Loading...
XSHG
600285
Market cap1.82bUSD
Jul 10, Last price  
21.72CNY
1D
-0.50%
1Q
0.51%
Jan 2017
70.77%
IPO
254.89%
Name

Henan Lingrui Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600285 chart
P/E
16.22
P/S
3.20
EPS
1.34
Div Yield, %
4.13%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
10.57%
Revenues
3.85b
+10.07%
392,177,875520,330,937423,244,212463,281,143381,238,790448,778,162562,700,777686,974,842826,274,1161,084,814,7741,439,313,4721,848,525,0842,053,113,1792,157,052,0002,331,577,4462,693,510,9183,001,862,2133,311,472,6063,500,831,2853,853,391,129
Net income
760m
+5.11%
12,880,56769,496,69310,476,57429,314,87748,557,68129,851,40542,453,613105,367,06376,170,887131,909,368345,772,179217,112,190243,263,846294,436,959325,489,253361,542,668465,304,600568,109,307722,550,725759,503,032
CFO
554m
-36.76%
26,763,98715,985,21643,720,671132,607,233040,487,86015,434,351127,269,669124,320,875156,818,48163,262,545105,972,634436,248,604450,154,297450,529,975845,686,168834,909,734813,428,748875,864,233553,882,713
Dividend
Jun 20, 20250.9 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1992 and headquartered in Xinyang, China, Henan Lingrui Pharmaceutical Co., Ltd. specializes in the production and distribution of pharmaceutical products throughout the Chinese market. The company offers a broad catalog of approximately 100 different medications, provided in ten distinct dosage formats such as adhesive plasters, tablets, capsules, granules, and tinctures. Prominent items in their product line include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, and Shenqi Hypoglycemic capsules.
IPO date
Oct 18, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT